Veradermics (MANE) Free Cash Flow (2025 - 2026)
Veradermics posted quarterly Free Cash Flow of -$21.2 million for Q1 2026, down 58.73% year-on-year from -$51.3 million in Q1 2025, and down 58.73% on a QoQ basis from -$13.3 million in Q1 2025.
Veradermics (MANE) has 2 years of Free Cash Flow data on file, last reported at -$21.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 58.73% year-over-year to -$21.2 million; the trailing twelve-month figure through Mar 2026 stood at -$34.5 million (changed N/A YoY), and the FY2025 full-year result was -$71.6 million, down 202.22% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$21.2 million, down from -$13.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$13.3 million in Q1 2025 and bottomed at -$21.2 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - | -21.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.17 Mn |
| Mar 31, 2026 | -21.17 Mn |
| Mar 31, 2025 | -13.34 Mn |
| Mar 31, 2025 | -13.34 Mn |